For research use only. Not for therapeutic Use.
Alogabat (Cat No.: I021808) is an investigational oral positive allosteric modulator of GABA-A receptors, developed for the treatment of neurological disorders such as essential tremor and epilepsy. By enhancing GABAergic inhibitory signaling in the central nervous system, alogabat helps stabilize neural activity and reduce excessive excitability associated with motor and seizure disorders. It offers the potential for once-daily dosing with durable symptom control. Alogabat is currently in clinical trials and shows promise as a targeted therapy for movement and seizure-related conditions.
| CAS Number | 2230009-48-8 |
| Synonyms | 6-[[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy]-N-(oxan-4-yl)pyridazine-3-carboxamide |
| Molecular Formula | C21H23N5O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H23N5O4/c1-13-3-4-15(11-22-13)20-17(14(2)30-26-20)12-29-19-6-5-18(24-25-19)21(27)23-16-7-9-28-10-8-16/h3-6,11,16H,7-10,12H2,1-2H3,(H,23,27) |
| InChIKey | ACZCJTHHWMBFKC-UHFFFAOYSA-N |
| SMILES | CC1=NC=C(C=C1)C2=NOC(=C2COC3=NN=C(C=C3)C(=O)NC4CCOCC4)C |
| Reference | [1]. Bernd Buettelmann, et al. New isoxazolyl ether derivatives as gaba a alpha5 pam. Patent WO2018104419A1. |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
